NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V.（NAMS）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
nams · 股价预测 · 10 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 10 位华尔街分析师
Buy
10 位分析师
共识
评级分布
12 个月目标价
High
$55.00
Consensus
$49.00
+56.9% upside
Low
$45.00
Median: $47 · Last Close: $31.23
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$49.00
56.9% upside
High Target
$55
76.1%
Low Target
$45
44.1%
Current Price
$31.23
as of today
Based on analyst price targets, the NAMS stock price prediction for the next 12 months ranges from $45 to $55. The consensus NAMS price forecast of $49.00 implies 56.9% upside from the current price of $31.23.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $29.66 | ↓ 5.00% |
1-day model range: $29.43–$29.9. Peak: $29.9 (-5.00%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $31 | -1.1% |
| 2028 | $31 | -1.8% |
| 2029 | $31 | -2.1% |
| 2030 | $30 | -2.4% |
| 2031 | — | -2.5% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · NAMS · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-02-19 | Guggenheim | Maintains | Buy→Buy |
| 2026-02-18 | Needham | Maintains | Buy→Buy |
| 2026-01-21 | RBC Capital | Maintains | Outperform→Outperform |
| 2025-12-16 | Stifel | Maintains | Buy→Buy |
| 2025-12-02 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2025-11-06 | RBC Capital | Maintains | Outperform→Outperform |
| 2025-11-05 | Needham | Maintains | Buy→Buy |
| 2025-10-17 | Citigroup | Maintains | Buy→Buy |
| 2025-08-07 | RBC Capital | Maintains | Outperform→Outperform |
| 2025-06-12 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on NewAmsterdam Pharma Company N.V. (NAMS) stock. Of the recent 29 rating actions, 0 were upgrades and 0 were downgrades. 10 analysts currently cover NAMS.
分析师推荐趋势
NAMS analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$29M
↓ 93.0% YoY
Revenue Next Year
$171M
↑ 480.8% YoY
EPS This Year
$-1.81
EPS Next Year
$-1.39
↓ 22.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast NAMS EPS of $-1.81 for the current fiscal year, based on estimates from 10 analysts. The NAMS revenue forecast is $29M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
NAMS 股价预测由两类独立数据源支撑：来自 10 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。NAMS 的共识目标价为 $49.00（+56.9% 上行空间），分析师共识为 Buy。
NAMS 的短期预测（明日）为 $29.66（-5.00%）。 NAMS 对 2027 年的股价预测均值为 $31。 NAMS 对 2030 年的预测区间为 $28–$33。
NewAmsterdam Pharma Company N.V. 在 NASDAQ 上市，代码 NAMS。NAMS 在 2027 年的整体展望偏积极，在覆盖分析师中约 90% 对应 Buy 共识。
常见问题
NAMS 预测 · 8 个问题根据 10 位华尔街分析师，NAMS 的 12 个月平均目标价为 $49.00，最高 $55.00、最低 $45.00。若有图表，中位目标价可在上方查看。相对当前价 $31.23，隐含约 +56.9% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.